Quantcast

Latest Nikolaus Friedreich Stories

2009-12-15 08:00:00

WALTHAM, Mass., Dec. 15 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association (MDA). This grant will support the completion of preclinical GLP toxicology testing and GMP manufacture of a drug candidate for human clinical trials. Support from the MDA not only provides important funding for...

2009-09-26 08:58:00

Discovery takes researchers 1 step closer to human clinical trials and could improve understanding of other diseases Using clever chemistry, a Scripps Research team has pinpointed the enzyme target of a drug group that stops the progression of the devastating disease Friedreich's ataxia in mice and may do the same for humans. The findings, developed in collaboration with scientists from Repligen Corporation, help advance this treatment approach one step closer toward human clinical trials,...

2009-09-25 11:15:00

WALTHAM, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) reported today publication of research that identifies histone deacetylase 3 (HDAC 3) as an important enzyme target for therapeutic intervention in Friedreich's ataxia. These research findings confirm the drug target of the HDAC inhibitors that Repligen is currently developing for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia. The study entitled "Chemical Probes...

2008-12-22 15:22:00

ST. PETERSBURG, Fla., Dec. 22 /PRNewswire/ -- On December 17th, the new Bonefish Grill restaurant located at 5062 4th Street North in St. Petersburg, opened its doors to friends and supporters of Friedreich's Ataxia Research Alliance for Heineken with a Heart, a social event sponsored by Bonefish Grill, SafeCall and Heineken USA to benefit local charities. (Logo: http://www.newscom.com/cgi-bin/prnh/20080212/CLTU083LOGO ) Guests took part in complimentary Bonefish Grill delights...

2008-10-10 09:00:18

LIESTAL, SWITZERLAND--(Marketwire - Oct. 10, 2008) - Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today the launch of CATENA(R) (idebenone) in Canada. The drug is indicated for the treatment of Friedreich's Ataxia, a rare neuromuscular disease that results in the degeneration of nerve and muscle tissue. Catena is the first and only approved therapy in Canada to treat this devastating genetic disorder. Santhera...

2008-07-24 12:01:22

Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia. Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena. Launch of Catena is anticipated by the end of October 2008. In clinical studies submitted to Health Canada as part of the approval process,...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.